2025-06-05 18:53 AD |
Food: 19g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO
|
2025-06-05 09:49 AD |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
|
2025-06-05 07:48 AD |
BAR, 0 pellet, normal mutes, no leftovers
|
2025-06-04 18:59 AD |
------------- LASER THERAPY ---------------- Power (joules): 312 Time: 5:12 Location: Right humerus Notes: Performed over the medial and lateral aspects of the wing with concentration over the patagium and pectoral muscle directly proximal to the wing as well.
Bandage change: Vetwrap, foam padding, and cast padding was removed. The entry site for the intramedullary pin had a feather wrapped around the bar. When the feather was removed, the pin tract was mildly erythematous with mild swelling and moisture present. The other pin tracts were clean with no swelling, erythema, or discharge. All pin tracts were cleaned with dilute betadine in saline applied with a cotton tipped applicator with special attention to the IM pin tract. A piece of cotton was cut to cover the pin tract, and the external fixator was rewrapped with cast padding, a foam pad, and vetwrap.
Physical therapy |
Limb/joint | Right wing | Type | PROM | | Elbow | Wrist | Before | 90 | 130 | After | 120 | 160 | Notes Performed under anesthesia. The joints were stretched and held in extension for 10-15 seconds at a time. Greater extension was able to be performed under anesthesia, and the joints, while stiff, glided smoothly. |
|
|
2025-06-04 16:20 AD |
Food: 38g, Ch Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
|
2025-06-04 09:18 AMS |
======= TREATMENT PLAN ======= NPO Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SID SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) BID PO Meloxicam: 0.12 ml (1.5 mg/ml soln) SID PO (0.5mg/kg SID dosing) Laser therapy: PT: PROM Wing Wound care/bandage change: . Use Triple Antibiotic Ointment ============================== d/c ceftiofur
|
2025-06-04 08:20 AD |
Weight: 337 grams NPO Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) BAR, 1 pellet, normal mutes, no leftovers Weight: Weight loss 8% (-31g)
|
2025-06-03 16:35 AD |
Food: 19g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
|
2025-06-03 07:57 AD |
Food: 22g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) BAR, no pellet, normal mutes, no leftovers
|
2025-06-02 16:52 PM |
40g M Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) Laser therapy: PT: PROM Wing Wound care/bandage change: . Use Triple Antibiotic Ointment
|
2025-06-02 14:57 AD |
------------- LASER THERAPY ---------------- Power (joules): 312 Time: 5:12 Location: Medial humerus, propagatium Notes: The medial aspect of the humerus was treated as well as the propagatium and propagatial tendon. The pectoralis muscles immediately proximal to the wing were covered as well.
Physical therapy |
Limb/joint | Right wing | Type | PROM | | Elbow | Wrist | Before | | | After | | | Notes Awake passive range of motion physical therapy performed on the elbow and glenoid joints. Decreased range of motion of both joints, more markedly decreased at the elbow. |
|
|
2025-06-02 08:28 SAK |
======= TREATMENT PLAN ======= NPO Ceftiofur Excede Q 96 hr: 0.07 ml (100 mg/ml) IM on 2025-06-05, 2025-06-09, 2025-06-13 Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SID SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) BID PO Meloxicam: 0.12 ml (1.5 mg/ml soln) SID PO (0.5mg/kg SID dosing) Laser therapy: PT: PROM Wing Wound care/bandage change: . Use Triple Antibiotic Ointment ==============================
|
2025-06-02 07:46 AD |
NPO Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) BAR, 0 pellets, normal mutes, no leftovers
|
2025-06-01 15:19 AD |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO
|
2025-06-01 09:24 AD |
Food: 19g M, Ch Ceftiofur Excede Q 96 hr: 0.07 ml (100 mg/ml) IM Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) BAR, 1 pellet, normal mutes, no L/O
|
2025-05-31 14:56 DBT |
Food: 23g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO
|
2025-05-31 10:08 DBT |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
|
2025-05-30 17:46 re |
Food:40g m Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO
|
2025-05-30 16:00 AD |
Physical therapy: Passive range of motion performed on elbow and shoulder joints. Arm and shoulder felt stiff during PT and has decreased range of motion of right wing.
|
2025-05-30 09:20 DBT |
NPO Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
BAR 1 pellet, Normal Mutes, NOLO
|
2025-05-29 16:09 DBT |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO
|
2025-05-29 11:24 re |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Meloxicam: 0.12 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
BAR, no pellet, normal mutes, no leftovers
|
2025-05-28 17:53 re |
======= TREATMENT PLAN ======= NPO Ceftiofur Excede Q 96 hr: 0.07 ml (100 mg/ml) IM on 2025-06-01, 2025-06-05, 2025-06-09, 2025-06-13 Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SID SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) BID PO Meloxicam: 0.12 ml (1.5 mg/ml soln) SID PO (0.5mg/kg SID dosing) ==============================
|
2025-05-28 17:40 MR |
80g m Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) PO Ceftiofur Excede Q 96 hr: 0.07 ml (100 mg/ml) IM
|
2025-05-28 16:00 AD |
Clinical Pathology Report:
Description: The smears have similar findings. There is abundant blood and a small amount of extracellular lipid. Leukocytes are present in type and number consistent with blood. Rare microfilaria are observed on two of the smears. The microfilaria are ~200 microns in length and 15-25 microns wide with a tapered tail and granular internal structure. There are no overt bacteria observed.
Opinion: Poorly cellular sample; blood and rare microfilaria.
Comments: The aspirates from the described mass contain only blood, with no tissue cells for interpretation. These findings could indicate that mass is a hematoma or an area of hemorrhage associated with the healing fracture. Additionally, there could be a poorly exfoliative mass. There are no overt bacterial organisms observed. Please use the results from the bacterial culture performed to guide potential treatment. The microfilaria observed may originate from subcutaneous tissues or blood and are generally considered non-pathogenic. Please correlate with clinical findings.
Cytology report |
Collection date | 2025-05-28 | Location | Proximal right humerus at most proximal ESF pin | Stain | Gram | Findings Findings could indicate the mass is a hematoma or an area of hemorrhage associated with the
healing fracture. Additionally, there could be a poorly exfoliative mass. There are no overt bacterial
organisms observed.
(Whole resport in main text box). | Diagnosis
|
|
|
2025-05-28 14:34 re |
Imagery report |
Date | 2025-05-28 | Type | Radiograph | Performed by | | Positioning | extended R caudocranial, extende | Equipment | Radiograph machine | Location | | Anesthesia | ISO via mask | Comments | In extended right caudocranial and extended right lateral view there are concerns regarding loss of cortex and lytic region surrounding the exit site of the most proximal external fixator pin. The appearance of the cortex appears to be more than a suspected halo artifact surrounding the pin, and there is concern of bacterial infiltration to the site. An ultrasound guided fine needle aspirate was taken from the site and submitted for cytology, anaerobic, and aerobic culture and susceptibility. |
|
|
2025-05-28 14:04 SAK |
======= TREATMENT PLAN ======= NPO Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SID SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.11 ml (100mg/ml soln) BID PO Meloxicam: 0.12 ml (1.5 mg/ml soln) SID PO (0.5mg/kg SID dosing) ==============================
|
2025-05-28 13:34 SAK |
Updated medication doses based on a latest weight of 368 g
|
2025-05-28 09:41 re |
Weight: 368 grams NPO Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
Weight gain 4% (+14g)
BAR, 1 pellet, normal mutes, no leftovers
|
2025-05-28 08:25 SAK |
======= TREATMENT PLAN ======= NPO Buprenorphine SR: 0.06 ml (1.8 mg/ml SR) SID SQ (PT Days only) Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) BID PO Meloxicam: 0.1 ml (1.5 mg/ml soln) SID PO (0.5mg/kg SID dosing) ==============================
|
2025-05-27 17:43 re |
Food: 21g m Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO
|
2025-05-27 13:30 re |
Food: 20g m Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
BAR, normal mutes, no leftovers, one pellet
|
2025-05-27 13:25 re |
BAR, normal mutes, no leftovers, one pellet
|
2025-05-26 15:24 Payton McCaleb |
Food: 21g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO
|
2025-05-26 08:59 Payton McCaleb |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) BAR, no pellet, 4g LO
|
2025-05-25 15:28 Payton McCaleb |
Food: 23g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
|
2025-05-25 09:12 Payton McCaleb |
Food: 21g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) BAR, no pellet, no LO
|
2025-05-24 15:32 Payton McCaleb |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO
|
2025-05-24 09:10 Payton McCaleb |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) BAR, no pellet, no LO
|
2025-05-23 15:33 JMH |
Food: 40g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO BID
|
2025-05-23 08:31 JMH |
NPO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO BID Meloxicam: 0.1 ml (1.5 mg/ml soln) PO SID (0.5mg/kg dosing) Radiograph: Right Wing Laser therapy: PT: PROM Wing
BAR No Pellet 0g LO
|
2025-05-22 17:05 JMH |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln)BID PO
|
2025-05-22 09:50 JMH |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO SID Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
BAR 1 Pellet 0g LO
|
2025-05-21 15:42 JMH |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing)
|
2025-05-21 09:06 JMH |
Weight: 354 grams Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) BAR No pellet No LO
PT: yesterday afternoon still showed some limited ROM in right elbow Wt gain (+16%) in last week (0.5 mg/kg meloxicam dose updated with new weight)
|
2025-05-20 16:54 JMH |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO BID
|
2025-05-20 10:34 JMH |
NPO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.1 ml (1.5 mg/ml soln) PO (0.5mg/kg dosing) PT: PROM Wing BAR 1 pellet No left overs
|
2025-05-20 09:20 AMS |
======= TREATMENT PLAN ======= NPO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) BID PO Meloxicam: 0.1 ml (1.5 mg/ml soln) SID PO (0.5mg/kg SID dosing) Laser therapy: PT: PROM Wing Wound care/bandage change: . Use Triple Antibiotic Ointment ============================== changed meloxicam to 0.5mg/kg SID dosing
|
2025-05-19 17:10 AN |
Food: 18g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.20 ml (1.5 mg/ml soln) PO (SID dosing)
|
2025-05-19 10:20 JMH |
======= TREATMENT PLAN ======= Food: 20g M, Ch BID Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) BID PO Meloxicam: 0.20 ml (1.5 mg/ml soln) SID PO (SID dosing) ==============================
|
2025-05-19 10:09 AN |
Food: 18g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.20 ml (1.5 mg/ml soln) PO (SID dosing)
|
2025-05-18 15:22 BT |
Food: 22g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO
|
2025-05-18 09:18 BT |
Food: 19g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.20 ml (1.5 mg/ml soln) PO (SID dosing) BAR, 1 pellet, NOLO, Normal Mutes
|
2025-05-17 15:21 BT |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO
|
2025-05-17 09:21 BT |
Food: 20g M, Ch Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.20 ml (1.5 mg/ml soln) PO (SID dosing) BAR, 1 pellet, NOLO
|
2025-05-16 16:09 JMH |
Food:44g M, Ch BID Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln)BID PO Meloxicam: 0.20 ml (1.5 mg/ml soln) PO (SID dosing) Laser therapy: right wing 312j PT: PROM right Wing Wound care/bandage change: cta w/ betadine solution and Triple Antibiotic Ointment
|
2025-05-16 10:52 Payton McCaleb |
NPO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.20 ml (1.5 mg/ml soln) PO (SID dosing) Laser therapy: PT: PROM Wing Wound care/bandage change: . Use Triple Antibiotic Ointment BAR, no pellet, no L/O
|
2025-05-16 10:04 AMS |
======= TREATMENT PLAN ======= NPO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) BID PO Meloxicam: 0.20 ml (1.5 mg/ml soln) SID PO (SID dosing) Laser therapy: PT: PROM Wing Wound care/bandage change: . Use Triple Antibiotic Ointment ============================== d/c TMS, decrease melox to SID
|
2025-05-15 16:24 JMH |
Food: 19g M, Ch TMS: 0.29 ml (48 mg/ml)BID PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln)BID PO Meloxicam: 0.18 ml (1.5 mg/ml soln)BID PO
|
2025-05-15 11:03 BT |
offered mealworms
|
2025-05-15 10:02 BT |
Food: 20g M, Ch TMS: 0.29 ml (48 mg/ml) PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
BAR, no pellets, no LO, Normal mutes
|
2025-05-15 08:58 SAK |
======= TREATMENT PLAN ======= Food: 20g M, Ch BID TMS: 0.29 ml (48 mg/ml) BID PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) BID PO Meloxicam: 0.18 ml (1.5 mg/ml soln) BID PO ==============================Update PT/Rads/Bchange/Laser dates
|
2025-05-14 16:39 JMH |
Food: 20g M, Ch (GIVE MEDS ORALLY) Watch food intake carefully TMS: 0.29 ml (48 mg/ml)BID PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln)BID PO Meloxicam: 0.18 ml (1.5 mg/ml soln) BID PO
|
2025-05-14 10:15 re |
Weight: 304 grams Food: 21g M, Ch (GIVE MEDS ORALLY) Watch food intake carefully TMS: 0.29 ml (48 mg/ml) PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO BAR, 1 pellet, no leftovers, normal mutes
Weight loss 5% (-17g)
|
2025-05-14 08:12 re |
======= TREATMENT PLAN ======= Food: 20g M, Ch (GIVE MEDS ORALLY) BID Watch food intake carefully TMS: 0.29 ml (48 mg/ml) BID PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) BID PO Meloxicam: 0.18 ml (1.5 mg/ml soln) BID PO ============================== d/c bupe
|
2025-05-13 17:16 Payton McCaleb |
Food: 40g M, Ch TMS: 0.29 ml (48 mg/ml) PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
|
2025-05-13 12:02 SAK |
NPO TMS: 0.29 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO BAR, normal mutes, no pellet, no leftovers
|
2025-05-13 11:20 re |
Weight: 321 grams Weight gain 16% (+45g)
|
2025-05-13 09:38 SAK |
======= TREATMENT PLAN ======= NPO TMS: 0.29 ml (48 mg/ml) BID PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ on 2025-05-16 Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) BID PO Meloxicam: 0.18 ml (1.5 mg/ml soln) BID PO Radiograph: Wing Wound care/bandage change: . Use Triple Antibiotic Ointment ============================== Bup on PT days only
|
2025-05-13 09:03 SAK |
======= TREATMENT PLAN ======= NPO TMS: 0.29 ml (48 mg/ml) BID PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SID SQ Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) BID PO Meloxicam: 0.18 ml (1.5 mg/ml soln) BID PO Radiograph: Wing Wound care/bandage change: . Use Triple Antibiotic Ointment ============================== Switch off AF.
|
2025-05-12 16:04 Payton McCaleb |
Assisted feed: 20g M, Ch cut up TMS: 0.29 ml (48 mg/ml) PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
|
2025-05-12 10:53 SAK |
Assisted feed: 22g M, Ch cut up TMS: 0.29 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
Pellet, normal mutes
|
2025-05-11 15:29 LIA |
Assisted feed: 21g M cut up TMS: 0.29 ml (48 mg/ml) PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
|
2025-05-11 09:34 LIA |
Assisted feed: 20g M cut up TMS: 0.29 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
BAR, bandaged intact, normal mutes, 0 pellets
|
2025-05-10 16:09 BC |
Assisted feed: 21g M cut up TMS: 0.29 ml (48 mg/ml) PO Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
|
2025-05-10 10:20 BC |
Assisted feed: 20g M cut up SQ fluids: 14ml LRS SW (maint) TMS: 0.29 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
Bandage remained intact
|
2025-05-10 08:45 Taylor Hopkins |
BAR, normal mutes, no pellet, no leftovers (assist fed), bandage intact
|
2025-05-09 17:05 BC |
Patient was anesthetized and its bandage was removed. Surgical site was assessed as well as the fracture site on the ventral aspect of the wing. External fixator still appears to be stable. Tissue appears to be healing appropriately with expected bruising and swelling present. Laser therapy was performed. Incision site and pin sites were cleaned with betadine and mupirocin ointment was placed around pins and incision. Range of motion was determined to be excellent in carpus and elbow. Bandage was replaced by placing telfa pads over the incision and around pins and then wrapping external fixator with cast padding and placing a Styrofoam padding over the cast padding. It was then wrapped with vet-wrap. No wing to body bandage was placed in order to give patient time to attempt to move affected wing.
------------- LASER THERAPY ---------------- Power (joules): 312 Time: 5 min 12 sec Location: From shoulder joint to elbow joint. Notes: Time was split between dorsal and ventral aspect of the wing.
|
2025-05-09 16:15 LIA |
Assisted feed: 20g M,AM +PM food combined SQ fluids: missed TMS: 0.29 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO Wound care/bandage change: . Use Triple Antibiotic Ointment
|
2025-05-09 10:19 SAK |
======= TREATMENT PLAN ======= Assisted feed: 20g M, Ch cut up BID SQ fluids: 14ml LRS SW (maint) SID until 2025-05-10 TMS: 0.29 ml (48 mg/ml) BID PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SID SQ Gabapentin Oral Susp 30 mg per kg: 0.08 ml (100mg/ml soln) BID PO Meloxicam: 0.18 ml (1.5 mg/ml soln) BID PO Wound care/bandage change: . Use Triple Antibiotic Ointment ============================== Add gaba
|
2025-05-09 07:21 LIA |
NPO bandage change BAR, normal mutes, no pellet, bandage intact, 25g leftovers
|
2025-05-08 16:41 BT |
Assisted feed: 20g M, Ch cut up
TMS: 0.29 ml (48 mg/ml) PO Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
|
2025-05-08 11:45 BT |
Food: 20g M, Ch cut up SQ fluids: 14ml LRS SW (maint) until 2025-05-10 TMS: 0.29 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Meloxicam: 0.18 ml (1.5 mg/ml soln) PO
|
2025-05-08 08:27 SAK |
======= TREATMENT PLAN ======= Assisted feed: 20g M, Ch cut up BID SQ fluids: 14ml LRS SW (maint) SID until 2025-05-10 TMS: 0.29 ml (48 mg/ml) BID PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SID SQ Meloxicam: 0.18 ml (1.5 mg/ml soln) BID PO Wound care/bandage change: . Use Triple Antibiotic Ointment ============================== Add sq LRS maint
|
2025-05-08 08:25 SAK |
======= TREATMENT PLAN ======= Assisted feed: 20g M, Ch cut up BID TMS: 0.29 ml (48 mg/ml) BID PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SID SQ Meloxicam: 0.18 ml (1.5 mg/ml soln) BID PO Wound care/bandage change: . Use Triple Antibiotic Ointment ==============================
|
2025-05-08 07:58 BC |
Patient was BAR Patient had 17 g left over. Patient had normal urate and feces but no pellet.
|
2025-05-07 17:00 BC |
Food: 21g M fed. 1 piece assist fed and left the other 3 pieces in the enclosure. TMS: 0.33 ml (48 mg/ml) PO Meloxicam: 0.22 ml (1.5 mg/ml soln) PO Wound care/bandage change: Patient was anesthetized and bandage was removed. Wound had minimal serosanguinous discharge. Patient also had moderate bruising and swelling that was to be expected. Range of motion was assessed. Range of motion of carpus and elbow was excellent. Laser therapy was performed. Pins were cleaned with betadine CTAs. Triple antibiotic ointment is applied at the pin sites and along incision site. Telfa padding was placed over incision and around pins and cast padding, Styrofoam pad, and vet wrap was placed around external fixator. Wing to body bandage was replaced.
------------- LASER THERAPY ---------------- Power (joules): 312 Time: 5 min 12 sec Location: From shoulder to elbow Notes: Time was split between dorsal and ventral aspect of wing. Laser therapy was performed around surgical area and wounds from fracture.
|
2025-05-07 16:43 re |
Electrophoresis Comments The albumin is decreased as is the overall total protein. This may reflect hydration, nephritis, hepatitis, or parasitism. By %TP, the beta globulins are increased and reflective of acute inflammation. Moderate to marked increases in this fraction can be observed with nephritis, hepatitis, dermatitis, and mycotic infection. Increases may also be observed with sarcocystosis and chronic chlamydiosis as well as mycobacteriosis. Specific beta globulin proteins which often manifest as a monoclonal appearing peak in this fraction are also increased in egg laying birds. Followup EPH may have prognostic value in this case.
Serum chemistry |
Collection date | 2025-05-07 | AST | 744 U/L | Phos | 3.3 mg/dl | BA | 1 umol/L | TP | 3.0 g/dl | CK | 9938 U/L | Alb | 0.0 g/dl | UA | 14.6 mg/dl | Glob | 0.0 g/dl | Glu | 358 mg/dl | K+ | 0.0 mmol/l | Ca | 10.0 mg/dl | Na+ | 0 mmol/l | | | AMY | 683 U/L | Hem , Lip , Ict |
|
CBC |
Collection date | 2025-05-07 | WBC count | 23100 | Corrected count | 23100 | Hets/Neut | 69% - 15939 | Bands | 0+ | Toxics | 0+ | Lymphs | 25% - 5775 | Eos | 1% - 231 | Mono | 3% - 693 | Baso | 2% - 462 | Thrombocytes | adequate | PI | 2 | Hemoproteus | NEG | Leukocytozoon | NEG | Plasmodium | NEG | Read by | UMiami Avian & Wildlife Lab | W BC Morphology: Reactive lymphocytes [Rare ] |
|
|
2025-05-07 16:05 BT |
Updated medication doses based on a latest weight of 276 g
|
2025-05-07 13:33 SAK |
Weight: 276 grams Drew 1ml blood from right jugular for intake labwork.
Weight loss 14% BW
PCV/TP |
Collection date | 2025-05-07 13:33:00 | PCV | 38 % | TS | 3.2 g\dl | Serum | |
|
Blood lead |
Collection date | 2025-05-07 | Level | 0.00 |
|
|
2025-05-07 12:20 BT |
Assist feed: 20g M, Ch TMS: 0.33 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Meloxicam: 0.22 ml (1.5 mg/ml soln) PO
|
2025-05-07 09:13 BC |
Weight: 276 grams Patient was weighed- 276 g (14% decrease)
|
2025-05-07 08:33 SAK |
======= TREATMENT PLAN ======= Food: 20g M, Ch BID TMS: 0.33 ml (48 mg/ml) BID PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SID SQ Meloxicam: 0.22 ml (1.5 mg/ml soln) BID PO Wound care/bandage change: . Use Triple Antibiotic Ointment ==============================
|
2025-05-06 18:27 BC |
Surgery report |
Procedure - Fracture repair - humerus | Performed by - Sokoloff | Surgery time - 98 minutes | Pre-surgical radiographs were performed. These radiographs confirmed
a diaphyseal humeral fracture, but also revealed numerous comminuted
portions of the fracture. It was decided that we would proceed
with surgery. Patient was placed in ventral recumbency and the
wing was prepped from shoulder to the elbow joint. An incision
was made above the fracture site. An IM pin was placed in a retrograde
fashion. The IM pin was inserted first into the proximal fragment,
exiting at the pectoral crest. The fracture was then reduced
and the pin was then driven into the distal fragment. The incision
was sutured closed with 5-0 PDS. 2 ESF pins were placed, one
in the proximal portion of the proximal fragment and one in the
distal portion of the distal fragment. An external fixator was
then connected to the ESF pins and the IM pin. The incision site
was cleaned with betadine and triple antibiotic ointment was
placed on the site of each pin. Telfa pads were placed around
each pin location and the fixator was wrapped with cast padding
and vet wrap. The right wing was then placed in a wing to body
wrap with silk tape. |
|
|
2025-05-06 16:03 Taylor Hopkins |
Food: 23g M offered TMS 0.33ml (48mg/ml) BID PO Meloxicam 0.22ml (1.5mg/ml) BID PO (1mg/kg) Wing Wrap Bandage intact
|
2025-05-06 11:18 AMS |
Food: Assist fed clean/organ meat from 1 mouse, did not leave any in cage due to sx later today TMS: 0.33 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Meloxicam: 0.22 ml (1.5 mg/ml soln) PO Wing wrap in place
42g leftovers (all from previous day)
AMS
|
2025-05-05 17:42 BC |
Fed 31 g M TMS: 0.33 ml (48 mg/ml) PO Meloxicam: 0.22 ml (1.5 mg/ml soln) PO Wound care/bandage change: Patient was placed under anesthesia and wing to body bandage was removed. Feathers were plucked at site of right humeral fracture and revealed small open wounds on the dorsum and ventrum of the wing. Wounds were cleaned with betadine and mupirocin ointment was placed around wounds. Telfa pads with tegaderm were placed over wounds on both ventral and dorsal aspect. Wing to body bandage was replaced with silk tape in order to stabilize the fracture. Anesthesia was started at 4:53 PM and ended at 5:14 PM Check wing wrap, replace if needed
|
2025-05-05 13:00 SAK |
NPO 34g LO from 5/4/25 Pellet/urates/feces present
|
2025-05-05 08:39 SAK |
======= TREATMENT PLAN ======= NPO TMS: 0.33 ml (48 mg/ml) BID PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SID SQ Meloxicam: 0.22 ml (1.5 mg/ml soln) BID PO Wound care/bandage change: Check wing wrap BID, replace if needed ==============================
|
2025-05-04 16:46 Taylor Hopkins |
Food: 16g M TMS: 0.33 ml (48 mg/ml) PO- put in food Meloxicam: 0.06 ml (5 mg/ml (Injectable)) SQ Check wing wrap, replace if needed- Patient was BAR and its wing to body wrap was still intact.
|
2025-05-04 09:52 Taylor Hopkins |
Food: 20g M TMS: 0.33 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Meloxicam: 0.06 ml (5 mg/ml (Injectable)) SQ Patient was BAR and had normal urates and feces. No pellets were noted. Patient had no left overs in enclosure. Wing to body bandage is still intact but had to be re-taped due to patient getting their foot stuck in the vet wrap.
|
2025-05-03 16:16 BC |
Food: 16g M SQ fluids: 8ml TMS: 0.33 ml (48 mg/ml) PO Meloxicam: 0.06 ml (5 mg/ml (Injectable)) SQ Check wing wrap, replace if needed
Patient was BAR and its wing to body wrap was still intact.
|
2025-05-03 11:13 BC |
Food: 16g M SQ fluids: 8ml until 2025-05-03 TMS: 0.33 ml (48 mg/ml) PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SQ Meloxicam: 0.06 ml (5 mg/ml (Injectable)) SQ
Patient was BAR and had normal urates and feces. No pellets were noted. Patient had no left overs in enclosure. Wing to body bandage appeared to still be intact
|
2025-05-02 17:51 AMS |
======= TREATMENT PLAN ======= Food: 16g M BID SQ fluids: 8ml BID until 2025-05-03 TMS: 0.33 ml (48 mg/ml) BID PO Buprenorphine SR: 0.05 ml (1.8 mg/ml SR) SID SQ Meloxicam: 0.06 ml (5 mg/ml (Injectable)) BID SQ Check wing wrap BID, replace if needed ==============================
|
2025-05-02 17:47 AMS |
Weight: 322 grams
|
2025-05-02 17:22 BT |
Food: 30 g. M
|
2025-05-02 16:38 SAK |
Sample |
Collection date | 2025-05-02 | Type | choanal/cloacal swab | Notes:
| Results: AI PCR : not detected |
|
|
2025-05-02 10:30 BC |
Weight: 322 grams, BCS: 2.5
------------- PHYSICAL EXAM FINDINGS ---------------- Attending Veterinarian: Dr. Amberly Sokoloff Observational examination Mentation: Quiet, alert, and responsive Posture: Patient has normal posture Overall appearance: Right wing is drooping Vital stats Heart rate: 460 bpm Respiratory rate: 80 brpm Auscultation: No abnormalities auscultated Mucous membranes: Pink Hydration: 5-10% Comments: Patient had a slow ulnar vein refill time. Oral cavity: Oral cavity was clear Choana: Choana was clear Glottis: Glottis was open and clear. Beak: Beak appeared normal. Cere/nares: Nares were open with no obstructions present. Eyes: No abnormalities present. Ears: No abnormalities present. Crop: No abnormalities present Feather quality: Numerous secondary flight feathers were blood feathers. Integument: Bleeding from dorsal aspect of right wing above proximal humerus where fracture is. A hippoboscid fly was also found on this patient. Wings: Left wing appeared normal. Right wing was dangling when patient was picked up. Patient appeared unable to move the right wing at all. Wings - Range of motion: Left wing's range of motion was normal. Right wing had limited to no range of motion. Wings - Patagium: No abnormalities noted Legs/Feet: No abnormalities noted Legs/Feet - Range of motion: Patient had normal range of motion in its legs. Legs/Feet - Plantar surface: No abnormalities noted Legs/Feet- Talons: No abnormalities noted Neurologic: Patient appeared to be neurologically stable Ceolom: No abnormalities noted on palpation BCS: 2 Vent: No abnormalities present Droppings: Not examined Uropygial gland: No abnormalities present Problem list: 1. Open transverse proximal diaphyseal fracture on right humerus 2. Hippoboscid fly Diagnosis: 1. Right humeral fracture on proximal diaphysis
Assessment: Overall, the patient's prognosis is gaurded. The patient appears unable to use the right wing and the fracture is close to the shoulder joint. Depending on how close this fracture is to the shoulder joint, fracture repair may not be possible. Plan: Tx: Patient was treated with meloxicam and buprenorphine for pain and a wing to body wrap was placed in order to stabilize the fractured wing. TMS was also given to treat any potential infections that could be occurring. Subcutaneous fluids were also administered to promote proper hydration. Dx: Radiographs of the fracture were performed and determined that there could potentially be enough space between the fracture and the shoulder joint to attempt fracture repair. Prognosis: Fair
|
2025-05-02 04:30 BC |
Whole body radiographs were taken. A VD view was taken and revealed a proximal diaphyseal humeral compound fracture. The fracture appeared to have potential to be repaired via surgery. Plan to retake radiographs
|